My Companies
Notification
Account
Log Out
Login
USFDA follow-up inspection at Cipla’s Pithampur facility resulted in seven Form 483 observations, creating regulatory uncertainty and potential remediation risk. The company committed to comprehensive corrective action.
Cipla Partners With Qilu To License Keytruda Biosimilar In US
Cipla Signs Exclusive License With SBP For TQB2102 HER2 ADC
Cipla Receives VAI Classification For InvaGen New York Inspection
Cipla Receives US FDA Approval For Generic Advair Diskus Inhaler
Cipla Appoints Dinesh Jain Global CFO As Ashish Adukia Moves To Internal Role